Stock Idea: FDA Softens

Biogen's new Alzheimer's, drug approval has investors pondering whether this is enough of a change in mindset to reshape opinions about gene editing companies. Bets are being placed in the options market.
To access this post, you must purchase Subscription Plan – AVC Pro.